The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
A major push to sharpen the future of cancer treatment is underway
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Highlights Mirvetuximab-based regimen promise
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
The presentations will showcase previously undisclosed data highlighting the expanding potential of Actinium’s Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies
Subscribe To Our Newsletter & Stay Updated
